Gujarat Themis Biosyn Q2 Results 2026: PAT ₹8 Cr (−40.6% YoY)
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
- Revenue
- ₹47Cr
- +12.1% YoY
- +8.4% QoQ
- Net profit
- ₹8Cr
- −40.6% YoY
- −23.5% QoQ
- Margin
- 37.4%
- −12.1 pp YoY
- −10.1 pp QoQ
Guidance rank: #79 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Gujarat Themis Biosyn Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue (Income from Operations) for the quarter ended September 30, 2026:. Quarter ended September 30, 2026:.
From Gujarat Themis Biosyn Ltd's Q2 FY27 earnings-call transcript · updated 14 Nov 2026.
How did Gujarat Themis Biosyn's revenue grow in the September 2026 quarter?
- Revenue (Income from Operations) for the quarter ended September 30, 2026:
- Standalone: ₹4,745.52 Lakhs
- Consolidated: ₹4,992.07 Lakhs
- Revenue for the quarter ended September 30, 2025:
- Standalone: ₹4,234.88 Lakhs
- Consolidated: ₹4,234.88 Lakhs
- Year-on-year revenue growth (quarterly):
2 more points from Gujarat Themis Biosyn Ltd's call on revenue
Create a free account to keep reading this call
What happened to Gujarat Themis Biosyn's margins in Q2 FY27?
Quarter ended September 30, 2026:
Locked: what Gujarat Themis Biosyn Ltd said on margins
Also locked on this page: fundraising, order book
Free account, 30 seconds. No card needed.
What capex is Gujarat Themis Biosyn planning?
2 more points from Gujarat Themis Biosyn Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Gujarat Themis Biosyn raising money or cutting debt?
The presentation indicates the following fundraising and changes related to debt and equity:
Locked: what Gujarat Themis Biosyn Ltd said on fundraising
Also locked on this page: margins, order book
Free account, 30 seconds. No card needed.
How big is Gujarat Themis Biosyn's order book?
See what Gujarat Themis Biosyn Ltd said on order book & pipeline — free account, 30 seconds.
Gujarat Themis Biosyn Ltd — Quarterly revenue & net profit
Gujarat Themis Biosyn Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue | 47 | 42 | +12.1% | 44 | +8.4% |
| Operating profit (EBITDA) | 18 | 21 | -15.4% | 21 | -14.7% |
| Operating margin | 37.4% | 49.5% | -12.1 pp | 47.5% | -10.1 pp |
| Profit before tax | 11 | 19 | -41.1% | 15 | -27.2% |
| Net profit (PAT) | 8 | 14 | -40.6% | 11 | -23.5% |
| EPS (₹) | 0.72 | 1.31 | -45% | 1.02 | -29.4% |
Source: Gujarat Themis Biosyn Ltd's results filing to NSE (standalone), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹47 Cr, net profit ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsCapex ₹1,638 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
What Gujarat Themis Biosyn's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Orchid Pharma (Q2 FY27)
4,280.8 lakhs (~14.3% increase). Key results statement takeaways from Orchid Pharma Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Nectar Lifescience (Q2 FY27)
Quarterly EBITDA**: ₹52.7 crore, down 88% YoY . Key results statement takeaways from Nectar Lifescience Ltd's Q2 FY27 results statement — and how it ranks again
- Gufic BioScience (Q2 FY27)
288.4 crore, up from Rs. Key investor presentation takeaways from Gufic BioSciences Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
- KRM Ayurveda (Q2 FY27)
Q2 FY27 Total Income:** ₹3,529.95 Lakhs, a 48.08% year-on-year (YoY) increase from Q2 FY26 (₹2,383.80 Lakhs). Key investor presentation takeaways from KRM Ayurv
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Gujarat Themis Biosyn Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Gujarat Themis Biosyn Ltd Q2 FY27 results?
Revenue (Income from Operations) for the quarter ended September 30, 2026:. Quarter ended September 30, 2026:.
What is Gujarat Themis Biosyn Ltd share price analysis?
Gujarat Themis Biosyn Ltd currently shows a neutral. The stock trades at a P/E of 104.2 with a market cap of ₹5,074 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gujarat Themis Biosyn Ltd planning capital expenditure?
The presentation describes the following capex and capacity expansion projects:.
Keep Gujarat Themis Biosyn Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.